Patient characteristics
| . | All patients, n (%) . |
|---|---|
| Patients, n | 26 |
| Age at infusion, years (range) | 14.4 (4.0-24.5) |
| Male | 15 (58) |
| Follow-up, d (range) | 389 (53-800) |
| MRD-negative CR on d 28 | 20 (77) |
| Indication for CAR T therapy | |
| Primary refractory | 4 (15) |
| Relapse | 22 (85) |
| Disease status at start of lymphodepletion | |
| M1 marrow | 17 (65) |
| ≥M2 marrow | 9 (35) |
| Prior lines of systemic therapy, n | |
| 1-2 | 21 (81) |
| 3-5 | 5 (19) |
| Prior blinatumomab | |
| Yes | 7 (27) |
| No | 19 (73) |
| Prior allo-HCT | |
| Yes | 11 (42) |
| No | 15 (58) |
| TP53 mutation | |
| Yes | 2 (8) |
| No | 24 (92) |
| . | All patients, n (%) . |
|---|---|
| Patients, n | 26 |
| Age at infusion, years (range) | 14.4 (4.0-24.5) |
| Male | 15 (58) |
| Follow-up, d (range) | 389 (53-800) |
| MRD-negative CR on d 28 | 20 (77) |
| Indication for CAR T therapy | |
| Primary refractory | 4 (15) |
| Relapse | 22 (85) |
| Disease status at start of lymphodepletion | |
| M1 marrow | 17 (65) |
| ≥M2 marrow | 9 (35) |
| Prior lines of systemic therapy, n | |
| 1-2 | 21 (81) |
| 3-5 | 5 (19) |
| Prior blinatumomab | |
| Yes | 7 (27) |
| No | 19 (73) |
| Prior allo-HCT | |
| Yes | 11 (42) |
| No | 15 (58) |
| TP53 mutation | |
| Yes | 2 (8) |
| No | 24 (92) |